N-Aryl-sulfoximine-substituted pyrimidines as CDK-and/or...

Details N-Aryl-sulfoximine-substituted pyrimidines as CDK-and/or... N-Aryl-sulfoximine-substituted pyrimidines as CDK-and/or...

2006-03-22

2008-11-25

Wilson, James (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C544S301000

Reexamination Certificate

active

07456191

ABSTRACT:
This invention relates to pyrimidine derivatives of general formula (I)in which Q, R1, R2, R3, R4, R5, X, and m have the meanings that are contained in the description, as inhibitors of cyclin-dependent kinases and VEGF-receptor tyrosine kinases, their production as well as their use as medications for treatment of various diseases.

REFERENCES:
patent: 2004/0224966 (2004-11-01), Brumby et al.
patent: WO 02/096888 (2002-12-01), None
Coburn M D et al., “Oxidation of 3,6-diamino-1,2,4,5-tetrazine and 3,6-diamino-1,2,4,5-tetrazine and 3,6-bis(S, S-dimethylsulfilimino)-1,2,4,5-tetrazine,” Journal of Heterocyclic Chemistry, Dec. 1993, vol. 30, No. 6, pp. 1593-1595, XP002340372.
Claus P K et al., “N-Aryl sulfinimides” Tetrahedron, vol. 31, No. 6, 1975, pp. 505-510, XP002340373.
Pollak A et al., “Über Ringöffnungen einiger Azolo- und Azinoazine,” Monatshefte Für Chemie, vol. 103, No. 5, 1972, pp. 1591-1603, XP002340374.

Affiliated with

Also associated with

Rating

N-Aryl-sulfoximine-substituted pyrimidines as CDK-and/or... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with N-Aryl-sulfoximine-substituted pyrimidines as CDK-and/or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-Aryl-sulfoximine-substituted pyrimidines as CDK-and/or... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4046196